| Literature DB >> 29748016 |
Alexandre Chabrol1, Marie Mayenga2, Abdul Momen Hamid2, Sylvie Friard2, Hélène Salvator3, Hélèe Doubre2, Séverine Fraboulet2, Anne-Cécile Metivier2, Emilie Catherinot2, Elisabeth Rivaud2, Marie Camille Chaumais4, David Montani5, Louis Jean Couderc3, Colas Tcherakian6.
Abstract
We report here the first cases, to our knowledge, of pulmonary arterial hypertension induced by lorlatinib. It s the first time that a tyrosine kinase inhibitor for lung cancer is associated with pulmonary arteriel hypertension.Entities:
Keywords: ALK rearrangement; Lorlatinib; Lung cancer; Pulmonary hypertension; Tyrosine kinase inhibitor
Mesh：
Substances：
Year: 2018 PMID： 29748016 DOI： 10.1016/j.lungcan.2018.03.023
Source DB: PubMed Journal: Lung Cancer ISSN： 0169-5002 Impact factor: 5.705